



FOR IMMEDIATE RELEASE

Qualyst announces Predictive Liver Biliary Clearance Seminar in Cambridge

RESEARCH TRIANGLE PARK, N.C., U.S.A. (August 25, 2005)

Qualyst, Inc. today announced that the Company will be hosting a reception and seminar in Cambridge, MA on September 27, 2005. Industry experts will give insight as to the use of B-CLEAR® to predict hepatobiliary clearance and drug-to-drug interactions.

"Many pharmaceutical and biotechnology companies are searching for more effective in vitro methods to understand how drug transporters are involved in the overall bio-availability of drug candidates," said Scott E. Neville, President and Chief Executive Officer of Qualyst. "This reception is being held in response to the increased demand for B-CLEAR® and its many potential uses within a pharmaceutical or biotechnology organization."

B-CLEAR® is Qualyst's patented in vitro sandwich-cultured hepatocyte system for the assessment of hepatobiliary disposition, biliary clearance and drug transport.

About Qualyst, Inc.

Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualyst's products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research at the University of North Carolina at Chapel Hill in 2001. For additional information, please refer to the company's web site at www.Qualyst.com or call 919-313-6500.

CONTACT:

Ian Mehr
VP, Business Development
Qualyst, Inc.
info[AT]qualyst[DOT]com
919-313-6507
www.Qualyst.com